KR102543603B1 - 벤조이미다졸 유도체, 제조 방법 및 그것의 용도 - Google Patents
벤조이미다졸 유도체, 제조 방법 및 그것의 용도 Download PDFInfo
- Publication number
- KR102543603B1 KR102543603B1 KR1020197020604A KR20197020604A KR102543603B1 KR 102543603 B1 KR102543603 B1 KR 102543603B1 KR 1020197020604 A KR1020197020604 A KR 1020197020604A KR 20197020604 A KR20197020604 A KR 20197020604A KR 102543603 B1 KR102543603 B1 KR 102543603B1
- Authority
- KR
- South Korea
- Prior art keywords
- fluoro
- methyl
- pyridin
- pyrimidin
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016111457 | 2016-12-22 | ||
| CNPCT/CN2016/111457 | 2016-12-22 | ||
| CN2017080661 | 2017-04-14 | ||
| CNPCT/CN2017/080661 | 2017-04-14 | ||
| PCT/CN2017/117950 WO2018113771A1 (en) | 2016-12-22 | 2017-12-22 | Benzimidazole derivatives, preparation methods and uses theirof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190114971A KR20190114971A (ko) | 2019-10-10 |
| KR102543603B1 true KR102543603B1 (ko) | 2023-06-14 |
Family
ID=62624617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197020604A Active KR102543603B1 (ko) | 2016-12-22 | 2017-12-22 | 벤조이미다졸 유도체, 제조 방법 및 그것의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11053238B2 (https=) |
| EP (1) | EP3559000B1 (https=) |
| JP (1) | JP7105781B2 (https=) |
| KR (1) | KR102543603B1 (https=) |
| CN (1) | CN110234652B (https=) |
| AU (1) | AU2017379041B2 (https=) |
| CA (1) | CA3047876C (https=) |
| DK (1) | DK3559000T3 (https=) |
| ES (1) | ES2917377T3 (https=) |
| TW (1) | TWI732083B (https=) |
| WO (1) | WO2018113771A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| TW201920141A (zh) | 2017-08-15 | 2019-06-01 | 中國大陸商北京軒義醫藥科技有限公司 | Cdk4/6抑制劑及其用途 |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| CN113861191B (zh) | 2018-06-21 | 2023-09-19 | 贝达药业股份有限公司 | 抑制cdk4/6活性化合物的晶型及其应用 |
| MA55909A (fr) * | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | Inhibiteurs de cdk |
| CN111138455B (zh) * | 2020-01-16 | 2022-03-04 | 郑州大学 | 一种手性四氢呋喃并恶嗪稠合苯并咪唑衍生物及其制备方法和用途 |
| CN115427414A (zh) * | 2020-04-28 | 2022-12-02 | 贝达药业股份有限公司 | 稠环化合物及其在医药上的应用 |
| KR102269420B1 (ko) | 2020-09-18 | 2021-06-24 | 전용석 | 긴급대피용 마스크장치 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| MX2023008896A (es) * | 2021-02-03 | 2023-08-09 | Tuojie Biotech Shanghai Co Ltd | Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo. |
| CN112979567B (zh) * | 2021-03-05 | 2023-07-18 | 中国医科大学 | Cdk12小分子抑制剂的化合物及其应用 |
| CN117222411B (zh) * | 2021-03-24 | 2026-03-27 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| CN119522226A (zh) * | 2022-08-01 | 2025-02-25 | 江苏恒瑞医药股份有限公司 | 一种稠三环类衍生物的晶型及制备方法 |
| WO2025016439A1 (zh) * | 2023-07-19 | 2025-01-23 | 浙江同源康医药股份有限公司 | 用作cdk2/4蛋白激酶抑制剂的化合物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075074A1 (en) | 2008-12-22 | 2010-07-01 | Eli Lilly And Company | Protein kinase inhibitors |
| CN105153119A (zh) | 2015-09-11 | 2015-12-16 | 广州科擎新药开发有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| WO2016173505A1 (en) | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
| WO2017071516A1 (zh) | 2015-10-27 | 2017-05-04 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012002527A1 (ja) | 2010-07-02 | 2012-01-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| CA2954298A1 (en) | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
-
2017
- 2017-12-22 WO PCT/CN2017/117950 patent/WO2018113771A1/en not_active Ceased
- 2017-12-22 US US16/471,415 patent/US11053238B2/en active Active
- 2017-12-22 EP EP17882916.4A patent/EP3559000B1/en active Active
- 2017-12-22 DK DK17882916.4T patent/DK3559000T3/da active
- 2017-12-22 TW TW106145306A patent/TWI732083B/zh active
- 2017-12-22 CA CA3047876A patent/CA3047876C/en active Active
- 2017-12-22 KR KR1020197020604A patent/KR102543603B1/ko active Active
- 2017-12-22 CN CN201780078241.XA patent/CN110234652B/zh active Active
- 2017-12-22 ES ES17882916T patent/ES2917377T3/es active Active
- 2017-12-22 JP JP2019534709A patent/JP7105781B2/ja active Active
- 2017-12-22 AU AU2017379041A patent/AU2017379041B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075074A1 (en) | 2008-12-22 | 2010-07-01 | Eli Lilly And Company | Protein kinase inhibitors |
| WO2016173505A1 (en) | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
| CN105153119A (zh) | 2015-09-11 | 2015-12-16 | 广州科擎新药开发有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| WO2017071516A1 (zh) | 2015-10-27 | 2017-05-04 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3047876A1 (en) | 2018-06-28 |
| CN110234652A (zh) | 2019-09-13 |
| AU2017379041A1 (en) | 2019-07-25 |
| RU2019121937A (ru) | 2021-01-22 |
| AU2017379041B2 (en) | 2021-08-26 |
| TWI732083B (zh) | 2021-07-01 |
| CN110234652B (zh) | 2020-11-10 |
| EP3559000B1 (en) | 2022-03-23 |
| WO2018113771A1 (en) | 2018-06-28 |
| US20210130345A1 (en) | 2021-05-06 |
| EP3559000A1 (en) | 2019-10-30 |
| JP7105781B2 (ja) | 2022-07-25 |
| CA3047876C (en) | 2023-08-29 |
| KR20190114971A (ko) | 2019-10-10 |
| US11053238B2 (en) | 2021-07-06 |
| JP2020504747A (ja) | 2020-02-13 |
| TW201829406A (zh) | 2018-08-16 |
| EP3559000A4 (en) | 2020-05-27 |
| ES2917377T3 (es) | 2022-07-08 |
| DK3559000T3 (da) | 2022-06-07 |
| RU2019121937A3 (https=) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102543603B1 (ko) | 벤조이미다졸 유도체, 제조 방법 및 그것의 용도 | |
| AU2005304784B2 (en) | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases | |
| US20220402948A1 (en) | Egfr inhibitor, composition and preparation method therefor | |
| AU2015407300B2 (en) | 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof | |
| DK3129374T3 (en) | (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER | |
| US9956220B2 (en) | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | |
| CA2624649A1 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| JP2018507883A (ja) | 抗がん剤としての置換２−ｈ−ピラゾール誘導体 | |
| US20170267696A1 (en) | Certain protein kinase inhibitors | |
| US9475817B2 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | |
| CA3147422A1 (en) | Inhibitors of cyclin-dependent kinases | |
| JP2022530371A (ja) | ピリミド５員複素環化合物及び変異型ｉｄｈ２阻害薬としてのその使用 | |
| AU2021218497A1 (en) | Quinolyl phosphine oxide compound, and composition and application thereof | |
| US20080214560A1 (en) | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | |
| WO2016006921A1 (ko) | 약물 부작용이 감소된 급성골수성백혈병 표적치료제 | |
| CN111763217B (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
| RU2779534C2 (ru) | Производные бензимидазола, способы их получения и применения | |
| HK40009806A (en) | Benzimidazole derivatives, preparation methods and uses theirof | |
| HK40009806B (en) | Benzimidazole derivatives, preparation methods and uses theirof | |
| US20220177450A1 (en) | Piperazine amide derivative, preparation method therefor, and use thereof in medicine | |
| HK1161230A (en) | Protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |